Sublingual immunotherapy for allergic rhinitis: systematic review and meta-analysis

Area of Science:

• Allergy and Immunology
• Otolaryngology

Background:

• Allergic rhinitis significantly impairs quality of life, even with optimal antihistamine and corticosteroid treatment.
• Allergen injection immunotherapy is effective but carries risks of severe systemic reactions.
• Sublingual immunotherapy (SLIT) presents a safer alternative route for allergen immunotherapy.

Purpose of the Study:

• To evaluate the efficacy of sublingual immunotherapy (SLIT) compared to placebo.
• To assess reductions in symptoms and medication requirements for allergic rhinitis patients.

Main Methods:

• Systematic review and meta-analysis of randomized controlled trials (RCTs) identified through comprehensive database searches (Cochrane, MEDLINE, EMBASE, Scisearch) up to September 2002.
• Included 22 double-blind, placebo-controlled trials with 979 participants suffering from allergic rhinitis with proven allergen sensitivity.
• Analyzed data using standardized mean differences (SMD) with a random effects model, performing subgroup analyses by allergen type, age, and treatment duration.

Main Results:

• Overall, SLIT demonstrated a significant reduction in both allergic rhinitis symptoms (SMD -0.42) and medication requirements (SMD -0.43) compared to placebo.
• Subgroup analyses did not reveal a disproportionate benefit based on specific allergens administered.
• Efficacy did not clearly increase with longer treatment durations, and results in exclusively pediatric studies were inconclusive due to small sample sizes.

Conclusions:

• Sublingual immunotherapy is an effective treatment for reducing symptoms and medication needs in allergic rhinitis.
• SLIT offers a viable alternative to injection immunotherapy, potentially improving patient quality of life.
• Further research is needed to optimize treatment protocols, including allergen dosage, and to confirm efficacy in pediatric populations.